MedWatch

Lundbeck partner soon to seek approval for new Abilify Maintena version

Japanese Otsuka, Lundbeck's partner in sharing rights for Abilify Maintena, signals plans to seek marketing approval for a longer-acting version of the drug – a move that could extend the medication's patent protection.

Photo: Thomas Borberg

The term of Abilify Maintena's patent protection could be substantially extended. Japanese Otsuka, Lundbeck's partner for the drug, is in the process of preparing to seek approval for a new and longer-acting version of the medication.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs